$17.6 million secondary sale also planned with $13.2 million greenshoe
By Devika Patel
Knoxville, Tenn., June 5 – Ocular Therapeutix, Inc. said on Thursday that it priced a $70.4 million public sale of stock. The deal will be conducted alongside a $17.6 million secondary sale with a $13.2 million greenshoe.
The company will sell 3.2 million common shares at $22.00 per share, and the selling stockholders will sell 800,000 shares at the same price. The price per share is a 7.13% discount to the June 3 closing share price of $23.69.
Morgan Stanley, Cowen and Co. and RBC Capital Markets are the bookrunning managers.
Settlement is expected June 10.
The biopharmaceutical company is based in Bedford, Mass.
| Issuer: | Ocular Therapeutix, Inc.
|
| Issue: | Common stock
|
| Amount: | $70.4 million
|
| Shares: | 3.2 million
|
| Price: | $22.00
|
| Warrants: | No
|
| Bookrunners: | Morgan Stanley, Cowen and Co. and RBC Capital Markets
|
| Co-managers: | Nomura and BTIG
|
| Pricing date: | June 4
|
| Settlement date: | June 10
|
| Stock symbol: | Nasdaq: OCUL
|
| Stock price: | $23.69 at close June 3
|
| Market capitalization: | $470.8 million
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
